Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERα covalent antagonist (SERCA)
- 123 Downloads
H3B-6545, a novel selective estrogen receptor (ER)α covalent antagonist (SERCA) which inactivates both wild-type and mutant ERα, is in clinical development for the treatment of metastatic breast cancer. Preclinical studies were conducted to characterize the pharmacokinetics and metabolism of H3B-6545 in rat and monkeys.
The clearance and metabolic profiles of H3B-6545 were studied using rat, monkey and human hepatocytes, and reaction phenotyping was done using recombinant human cytochrome P450 enzymes. Blood stability, protein binding, and permeability were also determined in vitro. Pharmacokinetics of H3B-6545 was assessed after both intravenous and oral dosing. A nonclinical PBPK model was developed to assess in vitro–in vivo correlation of clearance.
H3B-6545 had a terminal elimination half-life of 2.4 h in rats and 4.0 h in monkeys and showed low to moderate bioavailability, in line with the in vitro permeability assessment. Plasma protein binding was similar across species, at 99.5–99.8%. Nine metabolites of H3B-6545 were identified in hepatocyte incubations, none of which were unique to humans. Formation of glutathione-related conjugate of H3B-6545 was minimal in vitro. H3B-6545, a CYP3A substrate, is expected to be mostly cleared via hepatic phase 1 metabolism. Hepatocyte clearance values were used to adequately model the time-concentration profiles in rat and monkey.
We report on the absorption and metabolic fate and disposition of H3B-6545 in rats and dogs and illustrate that in vitro–in vivo correlation of clearance is possible for targeted covalent inhibitors, provided reactivity is not a predominant mechanism of clearance.
KeywordsH3B-6545 Pharmacokinetics Metabolism Breast cancer Covalent antagonist
The authors want to thank the H3B-6545 team at H3 Biomedicine for fruitful discussions.
This study was funded by H3 Biomedicine Inc.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Research involving human and/or animal participants
All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.
- 6.Leung L, Yang X, Strelevitz TJ, Montgomery J, Brown MF, Zientek MA, Banfield C, Gilbert AM, Thorarensen A, Dowty ME (2017) Clearance prediction of targeted covalent inhibitors by in vitro–in vivo extrapolation of hepatic and extrahepatic clearance mechanisms. Drug Metab Dispos 45:1–7CrossRefGoogle Scholar
- 7.Colombo F, Smith S, Korpal M, Hao MH, Nix D, O’Shea M, Prajapati S, Wang J, Warmuth M, Smith PG, Rioux N (2018) In vitro-in vito correlation of clearance for H3B-5942, a novel selective ERα covalent antagonist (SERCA). In: 22nd North American ISSX meeting, abstract P10. https://bib.irb.hr/datoteka/947954.22nd_north_american_issx_meeting_abstract_book.pdf
- 8.Smith PG, Puyang X, Furman C et al (2017) Discovery and development of H3B-6545: a novel, oral, selective estrogen receptor covalent antagonist (SERCA) for the treatment of breast cancer. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017, AACR, Washington DC. Cancer Res 77(13 Suppl):Abstract nr DDT01-04Google Scholar
- 10.Pollack GM, Brouwer KLR, Demby KB, Jones JA (1990) Determination of hepatic blood flow in the rat using sequential infusions of indocyanine green and galactose. Drug Metab Dispos 18:197–202Google Scholar
- 11.Nakajima M, Nakamura S, Tokudome S, Shimada N, Yamazaki H, Yokoi T (1999) Azelastine N-demethylation by cytochrome P450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. Drug Metab Dispos 27:1381–1391Google Scholar
- 12.Drug development and drug interactions: table of substrates, inhibitors and inducers. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm Accessed 2 July 2018
- 16.Obach RS (1999) Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350–1359Google Scholar
- 19.Scheers E, Leclercq L, de Jong J, Bode N, Bockx M, Laenen A, Cuyckens F, Skee D, Murphy J, Sukbuntherng J, Mannens G (2015) Absorption, metabolism, and excretion of oral 14C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men. Drug Metab Dispos 43:289–297CrossRefGoogle Scholar
- 22.Commandeur JN, Stijntjes GJ, Vermeulen NP (1995) Enzymes and transport systems involved in the formation and disposition of glutathione S-conjugates. Role of bioactivation and detoxification mechanisms of xenobiotics. Pharmacol Rev 47:271–330Google Scholar
- 23.Dickinson PA, Cantarini MV, Collier J, Frewer P, Martin S, Pickup K, Ballard P (2016) Metabolic disposition of osimertinib in rats, dogs, and humans: insights into a drug designed to bind covalently to a cysteine residue of epidermal growth factor receptor. Drug Metab Dispos 44:1201–1212CrossRefGoogle Scholar